Log in to save activitiesYour saved activities will show here so that you can easily access them whenever you're ready. Log in hereCME & EducationLog in to keep track of your credits.
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Educational Initiatives Developed in Partnership
Overview
Treatment for Multiple Myeloma (MM) continues to rapidly evolve. There are now more active treatment regimens available for patients with MM than ever before. Patients are treated earlier, often with combination regimens, and for longer periods of time. These changes have led to improved response rates, depth of response, disease-free intervals, and survival. These educational programs tackle this rapidly evolving field and aid in development of optimal individualized care plans that take into consideration therapy-, disease-, and patient-specific factors.
Do you know how to leap the barriers of access and adherence to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and how to get your patients to goal?
Treatment for multiple myeloma (MM) has become increasingly complex. As more active treatments become available, treatment is increasingly personalized. Patients are often treated earlier, in combination, for longer periods of time, and with more lines of therapy after relapse. These educational programs are designed to tackle this rapidly evolving field and aid in development of optimized individualized care plans that take into consideration therapy-, disease-, and patient-specific factors.
